This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Role of the Fujinon Intelligent Chromo Endoscopy (FICE™) in Barrett's Esophagus

This study has suspended participant recruitment.
(This voluntary action is being taken by Fujinon in response to an inquiry by the US FDA regarding the potential use of FICE)
Information provided by (Responsible Party):
Kenneth K. Wang, Mayo Clinic Identifier:
First received: March 9, 2010
Last updated: August 2, 2017
Last verified: August 2017
The purpose of this study to assess post ablation, if there are areas of Barrett's mucosa post ablation and to assess the ability of the Fujinon FICE system to detect this, as compared to white light endoscopy. A subgroup will also be compared with laser confocal microscopy

Barrett's Esophagus

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of the Fujinon Intelligent Chromo Endoscopy (FICE™) for the Detection of Dysplasia in Barrett's Esophagus and in Post Ablation Barrett's Esophagus

Resource links provided by NLM:

Further study details as provided by Kenneth K. Wang, Mayo Clinic:

Primary Outcome Measures:
  • detection of dysplasic areas [ Time Frame: during surveillance endoscopy ]
    Areas of residual mucosa will be scored for being present, absent or suspicious. The ability of both FICE and white light endoscopy to find areas will be graded on the number of areas found, and the size of the areas estimated at the time of endoscopy

Estimated Enrollment: 150
Study Start Date: January 2010
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Surveillance Barrett's esophagus
Patients scheduled for endoscopic surveillance of Barrett's esophagus
Barrett's esophagus post ablation
Patients scheduled for surveillance endoscopy who have undergone ablative therapies (PDT, RF ablation) for their Barrett's esophagus


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Barrett's esophagus

Inclusion Criteria:

  • Visible Barrett's esophagus
  • Scheduled for Surveillance Endoscopy
  • Able to undergo endoscopy

Exclusion Criteria:

  • Unable to undergo endoscopy
  • Unable to stop blood thinning medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01084629

United States, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Kenneth K Wang, MD Mayo Clinic Rochester MN
  More Information

Responsible Party: Kenneth K. Wang, Kathy and Russ Van Cleve Professor of Gastroenterology Research, Mayo Clinic Identifier: NCT01084629     History of Changes
Other Study ID Numbers: 07-006981
Study First Received: March 9, 2010
Last Updated: August 2, 2017

Keywords provided by Kenneth K. Wang, Mayo Clinic:
Barrett's Esophagus

Additional relevant MeSH terms:
Barrett Esophagus
Digestive System Abnormalities
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases processed this record on September 21, 2017